Cluster composition

Functions

CategoryNameIntersectionWithQueryPValueGenesInTermGenesInQueryGenesInTermInQueryID
GeneOntologyCellularComponentSWI/SNF superfamily-type complex

BICRA SRCAP

7.36e-049692GO:0070603
GeneOntologyCellularComponentATPase complex

BICRA SRCAP

1.32e-0312992GO:1904949
GeneOntologyCellularComponentactin-based cell projection

PCDH15 ANTXR1

5.96e-0327892GO:0098858
PathwayWP_PATHWAYS_AFFECTED_IN_ADENOID_CYSTIC_CARCINOMA

CEBPA SRCAP

4.33e-046572M39682
Pubmed

Whole genome sequencing resource identifies 18 new candidate genes for autism spectrum disorder.

LMTK3 SRCAP

5.41e-06149228263302
Pubmed

Proteome-scale mapping of binding sites in the unstructured regions of the human proteome.

EIF4G3 LMTK3 BICRA

1.49e-044309335044719
InteractionSMARCC2 interactions

FNBP1 CEBPA BICRA SRCAP

1.09e-0535394int:SMARCC2
InteractionSMARCB1 interactions

FNBP1 CEBPA BICRA SRCAP

1.23e-0536494int:SMARCB1
InteractionSMARCC1 interactions

FNBP1 CEBPA BICRA SRCAP

1.52e-0538494int:SMARCC1
InteractionBZW1 interactions

FNBP1 ANTXR1 CEBPA

5.94e-0518393int:BZW1
CytobandEnsembl 112 genes in cytogenetic band chr19q13

CEBPA LMTK3 BICRA

1.30e-03119293chr19q13
ToppCellE16.5-samps-Mesenchymal-Myofibroblast-myofibroblast_-_smooth_muscle-like|E16.5-samps / Age Group, Lineage, Cell class and subclass

PCDH15 BICRA

3.03e-04132929633653dba1edee47d915212fb6e68426da49de5
ToppCellPBMC_fresh-frozen-Severe-critical_progression_d12-22-Lymphocytic-Lymphocytic_T-CD8-positive,_alpha-beta_T_cell-T_CD8_c06-TNF|Severe-critical_progression_d12-22 / Compartment, severity and other cell annotations on 10x 3' data (130k)

PCDH15 CEBPA

3.41e-0414092276b3fa924176426efb31112ed4d355407f0b218
ToppCell10x_3'_v2v3-Neoplastic-Differentiated-like-MES-like-MES-like_hypoxia_independent-E|10x_3'_v2v3 / Platform, Oncotype, Lineage, Cell_class, celltype (level4), mutation group

LMTK3 SRCAP

4.23e-0415692bb505f639dbcad2b788db62d6084c2cb4e884bec
ToppCell343B-Lymphocytic-NK_cells-NK_cell_E|343B / Donor, Lineage, Cell class and subclass (all cells)

FNBP1 SRCAP

4.29e-04157920362c04b7b0b5017964b3a73ee678ae53e7238d7
ToppCellE18.5-Immune-Immune_Lymphocytic_T/NK-Lymphocytic_ILC-NK-NK-NK_mature|E18.5 / Age_group by Lineage, Lineage_subclass, Cell_type, subtypes-by-prolif

FNBP1 BICRA

4.45e-04160924a0ae0a83a10dbfc13591f4d2228ba8bcd2c2275
ToppCellsevere-unassigned|World / disease stage, cell group and cell class

BICRA SRCAP

4.68e-0416492b3a45c150df6594debeeca400cc58d30ef662756
ToppCellsevere-unassigned|severe / disease stage, cell group and cell class

BICRA SRCAP

4.73e-0416592f9ddd547992fec065d539a1d0305acba8fc7d79c
ToppCellCerebellum-Neuronal-Inhibitory-iN1(Gad1Gad2_Th)|Cerebellum / BrainAtlas - Mouse McCarroll V32

EIF4G3 LMTK3

4.85e-04167929efb9511a211d0824bb97f82c1a5860c43d2138f
ToppCellCerebellum-Neuronal-Inhibitory|Cerebellum / BrainAtlas - Mouse McCarroll V32

EIF4G3 LMTK3

4.85e-0416792904c613aac3f9919a432b110bb1dcc832b5aec0a
ToppCelldroplet-Lung-nan-18m-Myeloid-myeloid_dendritic_cell|Lung / Lung_Trachea - method, tissue, subtissue, age, lineage, cell ontology and free annotation

FNBP1 CEBPA

5.08e-041719206fe7eeffc6e0735342b88e1d1ae26a9b477fece
ToppCellAT1_cells-Donor_07|World / lung cells shred on cell class, cell subclass, sample id

TICAM1 SRCAP

5.20e-0417392b29816427428c7053017477f59b828bf1357f3b2
ToppCell5'-Parenchyma_lung-Immune_Myeloid-Myeloid_monocytic-classical_monocyte-Classical_monocytes-Classical_monocytes_L.1.2.4.2|5' / 5'-vs-3', Tissue groups, Lineages, Lineage subclass, Cell_type2, Cell_subtype2_L4.5

TICAM1 LMTK3

5.38e-041769223bde9b9b4977b8cfe7d2a3ab8e8088ce9c6012c
ToppCelldroplet-Lung-immune-endo-depleted-3m-Myeloid|Lung / Lung_Trachea - method, tissue, subtissue, age, lineage, cell ontology and free annotation

FNBP1 CEBPA

5.75e-04182923dec003bad0f3716cf8163861a9d4302a7d6df8c
ToppCellRA-13._Vascular_Smooth_Muscle|RA / Chamber and Cluster_Paper

FNBP1 ANTXR1

5.81e-0418392818fd886e0188091310825f9145fa53328f2c979
ToppCellRA-13._Vascular_Smooth_Muscle|World / Chamber and Cluster_Paper

FNBP1 ANTXR1

5.81e-0418392cae2ee08f985a6f005b4b8e959e465350315156a
ToppCelldroplet-Marrow-BM-30m-Myeloid-Cd4_positive_Macrophages|Marrow / Spleen_Marrow_Thymus - method, tissue, subtissue, age, lineage, cell ontology and free annotation

ANTXR1 CEBPA

6.13e-0418892b2472a294b25fc2f0da7f18519fdcb9ca166c6f0
ToppCelldroplet-Marrow-BM-30m-Myeloid-macrophage|Marrow / Spleen_Marrow_Thymus - method, tissue, subtissue, age, lineage, cell ontology and free annotation

ANTXR1 CEBPA

6.13e-0418892bf77e59b9001c7f7ca17f81073f935f281a25a1f
ToppCellLPS_only-Stromal_mesenchymal-Matrix_Fibroblast-MatrixFB|LPS_only / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2

PCDH15 ANTXR1

6.20e-04189922a22b9fae70afb3dab8476f9c00e48a4df756410
ToppCellLPS-antiTNF-Stromal_mesenchymal-Matrix_Fibroblast-Diff_MatrixFB|LPS-antiTNF / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2

PCDH15 ANTXR1

6.20e-0418992a153b83314cf52808f685296cff8c95af3f4983d
ToppCellLA-13._Vascular_Smooth_Muscle|World / Chamber and Cluster_Paper

FNBP1 ANTXR1

6.20e-04189926b3e88751b95fc2173f2c3d5061ed632d0c5f01c
ToppCellControl-Fibroblasts|Control / group, cell type (main and fine annotations)

PCDH15 ANTXR1

6.26e-04190923a42a9b98d954685d38a741f44545898d0e3e9ce
ToppCell(1)_Control_(PBS)-(3)_LEPR+_perivascular_cells|World / Stress and Cell class

ANTXR1 CEBPA

6.26e-0419092ec0ab31266583a0966ac7615d5c0fabb7b7e66e8
ToppCellLPS-IL1RA+antiTNF-Stromal_mesenchymal-Matrix_Fibroblast-Diff_MatrixFB|LPS-IL1RA+antiTNF / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2

PCDH15 ANTXR1

6.26e-0419092841cd55861b43578d704418b9bc0af2e8b88323a
ToppCellLPS-IL1RA+antiTNF-Stromal_mesenchymal-Matrix_Fibroblast-Activated_MatrixFB|LPS-IL1RA+antiTNF / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2

PCDH15 ANTXR1

6.33e-0419192b13229bb7f3713a392271aaf5dbae3edd1b9fe5a
ToppCellnucseq-Mesenchymal-Fibroblastic-Fibroblastic_2-AF1|nucseq / Celltype signatures by Technology, Lineage, Lineage_subclass, Celltype_group, Cell_type2

PCDH15 ANTXR1

6.33e-04191926688cee34beee4f151ac17fccbc9c26a9aad72e1
ToppCellnucseq-Mesenchymal-Fibroblastic-Fibroblastic_2|nucseq / Celltype signatures by Technology, Lineage, Lineage_subclass, Celltype_group, Cell_type2

PCDH15 ANTXR1

6.39e-041929299ce9e3c4c50cf64ebb62145f2b5420efa0db309
ToppCellLPS-antiTNF-Stromal_mesenchymal-Matrix_Fibroblast|LPS-antiTNF / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2

PCDH15 ANTXR1

6.39e-0419292dcd924d6eb67d33ee9f5d3e8ab6e1d4283d6b708
ToppCellLPS_only-Stromal_mesenchymal|LPS_only / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2

PCDH15 ANTXR1

6.39e-0419292162d8b5858d150ecbbd1c9bf2b19c6c9cd50a158
ToppCellLPS-IL1RA+antiTNF-Stromal_mesenchymal-Matrix_Fibroblast|LPS-IL1RA+antiTNF / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2

PCDH15 ANTXR1

6.39e-04192926f4ef24dab544681304b7f8a9dc073e7edaa4cf5
ToppCellLPS-IL1RA+antiTNF-Stromal_mesenchymal|LPS-IL1RA+antiTNF / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2

PCDH15 ANTXR1

6.39e-04192923d0cb19f037f604253d7d728689aeaa94251e92b
ToppCell(1)_Control_(PBS)-(3)_LEPR+_perivascular_cells|(1)_Control_(PBS) / Stress and Cell class

ANTXR1 CEBPA

6.39e-041929240f380f5f0bed63a7404be050838ebd01ef08987
ToppCellLPS-IL1RA-Stromal_mesenchymal|LPS-IL1RA / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2

PCDH15 ANTXR1

6.39e-04192924e47a02007f562f29ba5910df64d32a0167d0bd1
ToppCellLPS-IL1RA-Stromal_mesenchymal-Matrix_Fibroblast-MatrixFB|LPS-IL1RA / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2

PCDH15 ANTXR1

6.39e-0419292deeecd26972241846b4cb998edf0c7a87ff0c4df
ToppCellPosterior_cortex-Neuronal|Posterior_cortex / BrainAtlas - Mouse McCarroll V32

EIF4G3 LMTK3

6.46e-0419392b4989e3436e84dbec3789b46057e0f7a0ebf09d4
ToppCellNS-critical-d_0-4-Epithelial-Basal|d_0-4 / Location, Severity, dps_group, Lineage and Cell class of Upper airway (combined)

ANTXR1 LMTK3

6.46e-04193921affb4c2e21712bde0d36ab736411fe36642cc6d
ToppCellMesenchymal-matrix_fibroblast_1_cell|World / Lineage, Cell type, age group and donor

PCDH15 ANTXR1

6.46e-0419392acad568621ed677031797b8c2e34dafea798d681
ToppCellLPS-IL1RA+antiTNF-Stromal_mesenchymal-Matrix_Fibroblast-MatrixFB|LPS-IL1RA+antiTNF / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2

PCDH15 ANTXR1

6.46e-0419392fb28717fadd06c3840636d25409ce80c9254bd34
ToppCellnucseq|World / Celltype signatures by Technology, Lineage, Lineage_subclass, Celltype_group, Cell_type2

EIF4G3 FNBP1

6.46e-0419392779276e775cb2492e8dd36436295a536084a6415
ToppCellAdult-Mesenchymal-matrix_fibroblast_1_cell-D231|Adult / Lineage, Cell type, age group and donor

PCDH15 ANTXR1

6.46e-0419392ef2f456c094e6e3c6ee81e0668c953cb8d0e1c0a
ToppCellLPS-antiTNF-Stromal_mesenchymal-Matrix_Fibroblast-MatrixFB|LPS-antiTNF / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2

PCDH15 ANTXR1

6.53e-041949260622bd2f75bfe4c37f721cb12f03dab33f2f58d
ToppCellFetal_29-31_weeks-Mesenchymal-matrix_fibroblast_1_cell|Fetal_29-31_weeks / Lineage, Cell type, age group and donor

PCDH15 ANTXR1

6.53e-0419492011e14d9ed1393275f892060e7708ffadcd0767f
ToppCellLPS-antiTNF-Stromal_mesenchymal|LPS-antiTNF / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2

PCDH15 ANTXR1

6.53e-04194926e13549f697f7478b34fe71f7dd9d63c5d3db22e
ToppCellLPS-antiTNF-Stromal_mesenchymal-Matrix_Fibroblast-Activated_MatrixFB|LPS-antiTNF / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2

PCDH15 ANTXR1

6.53e-041949289b706af2b25991fc2707eb24f49ba6ff3ae01f7
ToppCellfacs-Thymus-Thymus_Epithelium|Thymus / Spleen_Marrow_Thymus - method, tissue, subtissue, age, lineage, cell ontology and free annotation

PCDH15 ANTXR1

6.66e-04196926bc1187dfc4860a4e09032d7ea87ba3d9fe9f363
ToppCellChildren_(3_yrs)-Mesenchymal|Children_(3_yrs) / Lineage, Cell type, age group and donor

PCDH15 ANTXR1

6.66e-0419692bc94909f9b2dc08a59eef1914148b69720569c8f
ToppCellnucseq-Mesenchymal-Fibroblastic|nucseq / Celltype signatures by Technology, Lineage, Lineage_subclass, Celltype_group, Cell_type2

PCDH15 ANTXR1

6.66e-04196927d8505dac15fa59935ccf592afc54b04c4c6554f
ToppCellIPF-Endothelial-VE_Capillary_B|Endothelial / Disease state, Lineage and Cell class

PCDH15 ANTXR1

6.66e-04196928f0f72ead06abe02b575e443552eacc2151077ef
ToppCellfacs-Thymus-Thymus_Epithelium-18m|Thymus / Spleen_Marrow_Thymus - method, tissue, subtissue, age, lineage, cell ontology and free annotation

PCDH15 ANTXR1

6.66e-0419692c8c89e469402e11aa2a9561e859b6fd1fb66c39b
ToppCellnucseq-Mesenchymal|nucseq / Celltype signatures by Technology, Lineage, Lineage_subclass, Celltype_group, Cell_type2

PCDH15 ANTXR1

6.80e-04198928f52243ca8b9ba68a75ae411506a3a6de258eb97
ToppCell18-Distal-Epithelial|Distal / Age, Tissue, Lineage and Cell class

CEBPA SRCAP

6.87e-0419992592451359c7469496cd794df55ccc5f0d55bd661
ToppCellCOVID-19-COVID-19_Mild-Lymphocyte-T/NK-NK_activated|COVID-19_Mild / Disease, condition lineage and cell class

EIF4G3 SRCAP

6.93e-04200922281debd86e5d92e8fe0397aec9ef670800f7471
DrugCorticosterone [50-22-6]; Up 200; 11.6uM; MCF7; HT_HG-U133A

ANTXR1 BICRA SRCAP

4.21e-05184933244_UP
Drug17-AAG; Down 200; 1uM; MCF7; HT_HG-U133A_EA

FNBP1 CEBPA BICRA

4.35e-0518693831_DN
Drug17-AAG; Down 200; 1uM; MCF7; HT_HG-U133A_EA

TICAM1 FNBP1 CEBPA

4.35e-0518693916_DN
Druggeldanamycin; Down 200; 1uM; MCF7; HT_HG-U133A_EA

FNBP1 CEBPA BICRA

4.85e-0519393864_DN
DrugPaclitaxel [33069-62-4]; Up 200; 4.6uM; PC3; HT_HG-U133A

EIF4G3 CEBPA SRCAP

4.85e-05193936720_UP
DrugGuaifenesin [93-14-1]; Down 200; 20.2uM; MCF7; HT_HG-U133A

EIF4G3 CEBPA BICRA

4.93e-05194933431_DN
DrugCAY10397; Up 200; 10uM; PC3; HT_HG-U133A

EIF4G3 BICRA SRCAP

5.08e-05196937071_UP
DrugTHIP Hydrochloride; Up 200; 22.6uM; HL60; HT_HG-U133A

TICAM1 BICRA SRCAP

5.08e-05196933132_UP
DrugTremorine dihydrochloride [300-68-5]; Up 200; 15uM; MCF7; HT_HG-U133A

TICAM1 ANTXR1 SRCAP

5.08e-05196936273_UP
DrugLactobionic acid [96-82-2]; Up 200; 11.2uM; HL60; HT_HG-U133A

EIF4G3 TICAM1 SRCAP

5.16e-05197931309_UP
DrugLobeline alpha (-) hydrochoride [134-63-4]; Down 200; 10.6uM; MCF7; HT_HG-U133A

EIF4G3 BICRA SRCAP

5.16e-05197932763_DN
DrugPhenindione [83-12-5]; Down 200; 18uM; MCF7; HT_HG-U133A

ANTXR1 BICRA SRCAP

5.16e-05197932868_DN
DrugMethylprednisolone, 6-alpha [83-43-2]; Down 200; 10.6uM; MCF7; HT_HG-U133A

TICAM1 BICRA SRCAP

5.16e-05197936785_DN
DrugZidovudine, AZT [30516-87-1]; Down 200; 15uM; MCF7; HT_HG-U133A

TICAM1 ANTXR1 BICRA

5.16e-05197933211_DN
DrugNorethindrone [68-22-4]; Down 200; 13.4uM; MCF7; HT_HG-U133A

FNBP1 CEBPA SRCAP

5.16e-05197937414_DN
DrugProcaine hydrochloride [51-05-8]; Down 200; 14.6uM; PC3; HT_HG-U133A

EIF4G3 TICAM1 SRCAP

5.16e-05197931796_DN
DrugTrimethadione [127-48-0]; Down 200; 28uM; HL60; HT_HG-U133A

TICAM1 BICRA SRCAP

5.24e-05198932486_DN
DrugSpironolactone [52-01-7]; Down 200; 9.6uM; MCF7; HT_HG-U133A

TICAM1 ANTXR1 SRCAP

5.24e-05198932226_DN
DrugFlucloxacillin sodium [1847-24-1]; Up 200; 8.4uM; HL60; HT_HG-U133A

TICAM1 BICRA SRCAP

5.24e-05198933128_UP
DrugDibucaine [85-79-0]; Down 200; 11.6uM; PC3; HT_HG-U133A

TICAM1 BICRA SRCAP

5.31e-05199934068_DN
DrugEthylnitrosourea

PCDH15 TICAM1 ANTXR1

1.64e-0429193ctd:D005038
DrugDB08464

EIF4G3 BICRA

8.59e-0411392CID011373270
DrugTopo

FNBP1 ANTXR1

1.57e-0315392CID000065577
Drugcobaltiprotoporphyrin

TICAM1 CEBPA

1.69e-0315992ctd:C007095
Drug0179445-0000 [211246-22-9]; Up 200; 10uM; MCF7; HT_HG-U133A

TICAM1 SRCAP

2.13e-03179923630_UP
DrugTiclopidine hydrochloride [53885-35-1]; Up 200; 13.4uM; MCF7; HT_HG-U133A

TICAM1 SRCAP

2.23e-03183921475_UP
DrugParthenolide [20554-84-1]; Up 200; 16.2uM; MCF7; HT_HG-U133A

TICAM1 SRCAP

2.25e-03184925530_UP
Druglomustine; Up 200; 100uM; MCF7; HT_HG-U133A

TICAM1 CEBPA

2.28e-03185927045_UP
Drug17-AAG; Down 200; 1uM; MCF7; HT_HG-U133A

FNBP1 CEBPA

2.28e-03185925585_DN
DrugFelodipine [72509-76-3]; Up 200; 10.4uM; MCF7; HT_HG-U133A

TICAM1 SRCAP

2.33e-03187925294_UP
DrugHexetidine [141-94-6]; Up 200; 11.8uM; MCF7; HT_HG-U133A

TICAM1 SRCAP

2.33e-03187925420_UP
Drug17-AAG; Down 200; 1uM; MCF7; HT_HG-U133A_EA

CEBPA SRCAP

2.35e-0318892986_DN
DrugEconazole nitrate [24169-02-6]; Up 200; 9uM; MCF7; HT_HG-U133A

TICAM1 SRCAP

2.35e-03188927427_UP
Drug17-AAG; Down 200; 1uM; MCF7; HT_HG-U133A

TICAM1 FNBP1

2.37e-03189925578_DN
Drug0175029-0000 [211245-78-2]; Down 200; 1uM; MCF7; HT_HG-U133A

EIF4G3 CEBPA

2.37e-03189924716_DN
DrugAcacetin [480-44-4]; Down 200; 14uM; HL60; HT_HG-U133A

FNBP1 SRCAP

2.40e-03190922189_DN
Drug0179445-0000 [211246-22-9]; Up 200; 10uM; PC3; HT_HG-U133A

ANTXR1 SRCAP

2.40e-03190923733_UP
DrugLuteolin [491-70-3]; Down 200; 14uM; HL60; HT_HG-U133A

FNBP1 CEBPA

2.40e-03190923041_DN
DrugHarmol hydrochloride monohydrate [40580-83-4]; Down 200; 15.8uM; MCF7; HT_HG-U133A

EIF4G3 CEBPA

2.42e-03191926022_DN
DrugDisulfiram [97-77-8]; Up 200; 13.4uM; PC3; HT_HG-U133A

TICAM1 SRCAP

2.42e-03191925729_UP
Drug17-DMAG; Down 200; 0.1uM; MCF7; HT_HG-U133A

FNBP1 CEBPA

2.42e-03191925210_DN
Drugfluphenazine dihydrochloride; Down 200; 10uM; MCF7; HT_HG-U133A

ANTXR1 CEBPA

2.42e-03191925234_DN
Drug17-AAG; Down 200; 1uM; MCF7; HT_HG-U133A

FNBP1 CEBPA

2.42e-03191926944_DN
DrugHyoscyamine (L) [101-31-5]; Down 200; 13.8uM; MCF7; HT_HG-U133A

BICRA SRCAP

2.45e-03192922271_DN
DrugMesalamine [89-57-6]; Down 200; 26.2uM; HL60; HT_HG-U133A

TICAM1 BICRA

2.45e-03192926162_DN
Drug17-AAG; Down 200; 1uM; HL60; HT_HG-U133A

TICAM1 SRCAP

2.45e-03192926185_DN
Drug17-AAG; Down 200; 1uM; MCF7; HT_HG-U133A

FNBP1 CEBPA

2.45e-03192926978_DN
DrugPropoxycaine hydrochloride [550-83-4]; Down 200; 12uM; PC3; HT_HG-U133A

BICRA SRCAP

2.45e-03192927155_DN
DrugFlurandrenolide [1524-88-5]; Down 200; 9.2uM; PC3; HT_HG-U133A

EIF4G3 FNBP1

2.45e-03192927378_DN
Drug0317956-0000 [391210-11-0]; Up 200; 1uM; MCF7; HT_HG-U133A

TICAM1 SRCAP

2.45e-03192923858_UP
DrugAvermectin B1 [71751-41-2]; Up 200; 4.8uM; MCF7; HT_HG-U133A

TICAM1 SRCAP

2.45e-03192927218_UP
Drug17-AAG; Down 200; 1uM; MCF7; HT_HG-U133A

FNBP1 CEBPA

2.47e-03193926985_DN
DrugClotrimazole [23593-75-1]; Up 200; 11.6uM; MCF7; HT_HG-U133A

TICAM1 BICRA

2.47e-03193926207_UP
DrugQuercetine dihydrate [6151-25-3]; Down 200; 11.8uM; MCF7; HT_HG-U133A

FNBP1 SRCAP

2.47e-03193924846_DN
Drug0173570-0000 [211245-44-2]; Up 200; 10uM; MCF7; HT_HG-U133A

ANTXR1 SRCAP

2.47e-03193924712_UP
DrugCimetidine [51481-61-9]; Down 200; 15.8uM; MCF7; HT_HG-U133A

BICRA SRCAP

2.47e-03193921464_DN
DrugRilmenidine hemifumarate [54187-04-1]; Down 200; 8.4uM; PC3; HT_HG-U133A

BICRA SRCAP

2.47e-03193925107_DN
DrugRapamycin; Down 200; 0.1uM; MCF7; HT_HG-U133A

TICAM1 SRCAP

2.47e-03193925239_DN
Drug(+,-)-Octopamine hydrochloride [770-05-8]; Down 200; 21uM; PC3; HT_HG-U133A

FNBP1 SRCAP

2.47e-03193925050_DN
Drug17-DMAG; Down 200; 0.1uM; MCF7; HT_HG-U133A

CEBPA BICRA

2.50e-03194926933_DN
DrugCGX 0596987; Down 200; 20uM; PC3; HT_HG-U133A

BICRA SRCAP

2.50e-03194926417_DN
DrugParbendazole [14255-87-9]; Up 200; 16.2uM; PC3; HT_HG-U133A

ANTXR1 CEBPA

2.50e-03194923799_UP
DrugAlclometasone dipropionate [667634-13-2]; Up 200; 7.6uM; PC3; HT_HG-U133A

BICRA SRCAP

2.50e-03194925752_UP
DrugLoxapine succinate [27833-64-3]; Up 200; 9uM; MCF7; HT_HG-U133A

TICAM1 SRCAP

2.50e-03194925293_UP
DrugAcyclovir [59277-89-3]; Down 200; 17.8uM; MCF7; HT_HG-U133A

ANTXR1 SRCAP

2.50e-03194925278_DN
Drug0316684-0000 [391209-55-5]; Down 200; 10uM; PC3; HT_HG-U133A

TICAM1 SRCAP

2.50e-03194927098_DN
DrugPHA-00846566E [724718-26-7]; Up 200; 10uM; PC3; HT_HG-U133A

TICAM1 FNBP1

2.50e-03194927086_UP
DrugAltretamine [654-05-6]; Down 200; 19uM; MCF7; HT_HG-U133A

TICAM1 CEBPA

2.50e-03194926467_DN
Drug5155877; Up 200; 10uM; MCF7; HT_HG-U133A

TICAM1 SRCAP

2.50e-03194926549_UP
DrugFlurandrenolide [1524-88-5]; Down 200; 9.2uM; MCF7; HT_HG-U133A

ANTXR1 SRCAP

2.50e-03194926039_DN
DrugChloramphenicol [56-75-7]; Down 200; 12.4uM; PC3; HT_HG-U133A

TICAM1 SRCAP

2.50e-03194925047_DN
DrugLY 294002; Down 200; 10uM; MCF7; HT_HG-U133A

TICAM1 CEBPA

2.50e-03194925587_DN
DrugAcetylsalicylsalicylic acid [530-75-6]; Down 200; 13.4uM; MCF7; HT_HG-U133A

TICAM1 SRCAP

2.50e-03194926778_DN
DrugDyclonine hydrochloride [536-43-6]; Down 200; 12.2uM; MCF7; HT_HG-U133A

EIF4G3 SRCAP

2.50e-03194927423_DN
DrugMethocarbamol [532-03-6]; Down 200; 16.6uM; PC3; HT_HG-U133A

ANTXR1 BICRA

2.50e-03194922111_DN
DrugSpiramycin [8025-81-8]; Up 200; 4.8uM; MCF7; HT_HG-U133A

TICAM1 SRCAP

2.53e-03195923844_UP
DrugTranylcypromine hydrochloride [1986-47-6]; Down 200; 23.6uM; MCF7; HT_HG-U133A

TICAM1 SRCAP

2.53e-03195922264_DN
DrugCP-690334-01 [459212-38-5]; Down 200; 1uM; MCF7; HT_HG-U133A

CEBPA SRCAP

2.53e-03195923909_DN
DrugHydrastinine hydrochloride [4884-68-8]; Down 200; 16.4uM; MCF7; HT_HG-U133A

ANTXR1 SRCAP

2.53e-03195922283_DN
DrugMycophenolic acid [24280-93-1]; Down 200; 12.4uM; PC3; HT_HG-U133A

BICRA SRCAP

2.53e-03195924019_DN
DrugRemoxipride Hydrochloride [73220-03-8]; Up 200; 9.8uM; HL60; HT_HG-U133A

BICRA SRCAP

2.53e-03195923124_UP
DrugChlorambucil [305-03-3]; Down 200; 13.2uM; MCF7; HT_HG-U133A

TICAM1 SRCAP

2.53e-03195924345_DN
DrugBupivacaine hydrochloride [18010-40-7]; Up 200; 12.4uM; MCF7; HT_HG-U133A

TICAM1 SRCAP

2.53e-03195927435_UP
Drughaloperidol; Down 200; 10uM; HL60; HT_HG-U133A

TICAM1 SRCAP

2.53e-03195926163_DN
Diseasered blood cell density measurement

EIF4G3 ANTXR1 CEBPA

1.94e-0388093EFO_0007978
Diseasebasophil percentage of leukocytes

EIF4G3 CEBPA

2.34e-0324392EFO_0007992
Diseasemean corpuscular hemoglobin concentration

EIF4G3 ANTXR1 CEBPA

3.71e-03110593EFO_0004528
Diseasesmoking status measurement

EIF4G3 PCDH15 BICRA

4.26e-03116093EFO_0006527

Protein segments in the cluster

PeptideGeneStartEntry
PPAPHCPPPPPSAPT

ANTXR1

516

Q9H6X2
TDPSTPPAPPTPPHP

LMTK3

1381

Q96Q04
PPPSIPCPPPPSASF

PCDH15

1821

Q96QU1
SPHQPPPPPPASASP

FNBP1

336

Q96RU3
TPPPTPVPSPHPAPA

CEBPA

226

P49715
SRPPSEPPLHPCPPP

BICRA

811

Q9NZM4
PTPPTPPASPPHTPV

EIF4G3

416

O43432
PPPACTPPPAHTPPP

SRCAP

2501

Q6ZRS2
PPPPPPPSSTPCSAH

TICAM1

361

Q8IUC6